CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 79 enrolled
Drug / intervention
Alpinia galanga formulation +3 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05170113
NCT05170113N/ACompleted

A Pilot, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Effectiveness and Safety of an Alpinia Galanga Formulation, Theacrine Formulation, and Caffeine Formulation on Fatigue, Mental Acuity, and Cognitive Health Among Overall Healthy Participants

Supplement Formulators, Inc.·interventional·Posted Dec 27, 2021·Updated Jul 28, 2022

In Brief

A clinical study evaluating Alpinia galanga formulation, Theacrine formulation, and 2 other interventions for Fatigue. Completed, enrolled 79 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the effectiveness and safety of the Alpinia galanga formulation, Theacrine formulation, and Caffeine formulation on fatigue, mental acuity, and cognitive health among overall healthy participants

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFatigue
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedDec 27, 2021
Enrollment StartNov 2, 2021
Primary CompletionMay 31, 2022
TodayJul 1, 2026
Enrollment to primary: 7 monthsPosted 4.5 years ago

Interventions

Alpinia galanga formulationdietary

Alpinia galanga formulation capsule- 1 capsule daily

Theacrine formulationdietary

Theacrine formulation capsule- 1 capsule daily

Caffeine formulationdietary

Caffeine formulation capsule- I capsule daily

Placebodietary

Placebo capsule- 1 capsule daily